Deal overview
| Target | UPJOHN INC |
|---|---|
| Bidder | MYLAN NV |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Jul 29, 2019 |
| Abstract | On 29 July 2019, it was announced that the Dutch registered, Nasdaq listed, pharmaceuticals company Mylan NV was to acquire Upjohn Inc, the generic medicines business of the quoted US pharmaceuticals group, Pfizer Inc. The combination would be effected using an all-stock Reverse Morris Trust mechanism whereby Upjohn would be spun off or split off to Pfizer shareholders and ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
